These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 31595568)

  • 1. Immune checkpoint inhibitor-induced diarrhea: Clinicopathological study of 11 patients.
    Yanai S; Nakamura S; Kawasaki K; Toya Y; Akasaka R; Oizumi T; Ishida K; Sugai T; Matsumoto T
    Dig Endosc; 2020 May; 32(4):616-620. PubMed ID: 31595568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medication-specific variations in morphological patterns of injury in immune check-point inhibitor-associated colitis.
    Isidro RA; Ruan AB; Gannarapu S; Raj D; Rahma O; Grover S; Srivastava A
    Histopathology; 2021 Mar; 78(4):532-541. PubMed ID: 32931028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infliximab for severe colitis associated with nivolumab followed by ipilimumab.
    Fukumoto T; Fujiwara S; Tajima S; Tamesada Y; Sakaguchi M; Oka M; Nishigori C
    J Dermatol; 2018 Jan; 45(1):e1-e2. PubMed ID: 28891241
    [No Abstract]   [Full Text] [Related]  

  • 4. From ICI to ICU: Ipilimumab and Nivolumab-Induced Immune Checkpoint Inhibitor Colitis.
    Zhou W; Frye J; Soroudi C; Triadafilopoulos G; Berry R
    Dig Dis Sci; 2022 Mar; 67(3):800-803. PubMed ID: 34159488
    [No Abstract]   [Full Text] [Related]  

  • 5. Gastrointestinal Adverse Events Induced by Immune-Checkpoint Inhibitors.
    Yanai S; Toya Y; Sugai T; Matsumoto T
    Digestion; 2021; 102(6):965-973. PubMed ID: 34515105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune checkpoint inhibitor induced colitis: A nationwide population-based study.
    Farha N; Alkhayyat M; Lindsey A; Mansoor E; Saleh MA
    Clin Res Hepatol Gastroenterol; 2022 Jan; 46(1):101778. PubMed ID: 34332139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitis.
    Mooradian MJ; Wang DY; Coromilas A; Lumish M; Chen T; Giobbie-Hurder A; Johnson DB; Sullivan RJ; Dougan M
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32414860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Colonoscopic evaluation of diarrhea/colitis occurring as an immune-related adverse event.
    Yamauchi Y; Arai M; Akizue N; Ohta Y; Okimoto K; Matsumura T; Fan MM; Imai C; Tawada A; Kato J; Kato N; Takiguchi Y
    Jpn J Clin Oncol; 2021 Mar; 51(3):363-370. PubMed ID: 33290513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune checkpoint Inhibitor-Induced diarrhea and Colitis: Incidence and Management. A systematic review and Meta-analysis.
    Nielsen DL; Juhl CB; Chen IM; Kellermann L; Nielsen OH
    Cancer Treat Rev; 2022 Sep; 109():102440. PubMed ID: 35917654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endoscopical and pathological dissociation in severe colitis induced by immune-checkpoint inhibitors.
    de Andrea CE; Perez-Gracia JL; Castanon E; Ponz-Sarvise M; Echeveste JI; Melero I; Sanmamed MF; Rodriguez-Ruiz ME
    Oncoimmunology; 2020 May; 9(1):1760676. PubMed ID: 32934876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical, Endoscopic, and Histologic Characteristics of Ipilimumab-Associated Colitis.
    Verschuren EC; van den Eertwegh AJ; Wonders J; Slangen RM; van Delft F; van Bodegraven A; Neefjes-Borst A; de Boer NK
    Clin Gastroenterol Hepatol; 2016 Jun; 14(6):836-842. PubMed ID: 26748223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endoscopic and Histologic Features of Immune Checkpoint Inhibitor-Related Colitis.
    Wang Y; Abu-Sbeih H; Mao E; Ali N; Qiao W; Trinh VA; Zobniw C; Johnson DH; Samdani R; Lum P; Shuttlesworth G; Blechacz B; Bresalier R; Miller E; Thirumurthi S; Richards D; Raju G; Stroehlein J; Diab A
    Inflamm Bowel Dis; 2018 Jul; 24(8):1695-1705. PubMed ID: 29718308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Balancing the Checkpoint: Managing Colitis Associated with Dual Checkpoint Inhibitors and High-Dose Aspirin.
    Hammami MB; Gill R; Thiruvengadam N; Oh DY; Beck K; Mahadevan U; Kattah MG
    Dig Dis Sci; 2019 Mar; 64(3):685-688. PubMed ID: 30778872
    [No Abstract]   [Full Text] [Related]  

  • 14. Acute liver injury in the context of immune checkpoint inhibitor-related colitis treated with infliximab.
    Zhang HC; Luo W; Wang Y
    J Immunother Cancer; 2019 Feb; 7(1):47. PubMed ID: 30777137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Investigation of Nine Patients with Gastrointestinal Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors.
    Miyahara K; Noda T; Ito Y; Hidaka H; Fujimoto S; Takedomi H; Akutagawa T; Sakata Y; Shimamura T; Tominaga N; Yamaguchi D; Fujimoto K
    Digestion; 2020; 101(1):60-65. PubMed ID: 31801131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. COLAR: open-label clinical study of IL-6 blockade with tocilizumab for the treatment of immune checkpoint inhibitor-induced colitis and arthritis.
    Holmstroem RB; Nielsen OH; Jacobsen S; Riis LB; Theile S; Bjerrum JT; Vilmann P; Johansen JS; Boisen MK; Eefsen RHL; Marie Svane I; Nielsen DL; Chen IM
    J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36096534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune checkpoint inhibitor gastritis is often associated with concomitant enterocolitis, which impacts the clinical course.
    Haryal A; Townsend MJ; Baskaran V; Srivoleti P; Giobbie-Hurder A; Sack JS; Isidro RA; LeBoeuf NR; Buchbinder EI; Hodi FS; Grover S
    Cancer; 2023 Feb; 129(3):367-375. PubMed ID: 36377339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Outcome of Tofacitinib in Immune checkpoint Inhibitor Colitis.
    Bishu S; Melia J; Sharfman W; Lao CD; Fecher LA; Higgins PDR
    Gastroenterology; 2021 Feb; 160(3):932-934.e3. PubMed ID: 33096100
    [No Abstract]   [Full Text] [Related]  

  • 19. Toxic epidermal necrolysis occurring with immune checkpoint inhibitors.
    Gopee NH; Gourley AM; Oliphant TJ; Hampton PJ
    Dermatol Online J; 2020 Aug; 26(8):. PubMed ID: 32941713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recognizing encephalopathy in immune checkpoint inhibitor therapy: A single-center experience.
    Wei D; Zhou DJ; Datta P; Taraschenko O
    Cancer Med; 2021 May; 10(9):2978-2986. PubMed ID: 33660430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.